Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

V. Tomassini, L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, Carlo Pozzilli

Research output: Contribution to journalArticlepeer-review


The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P

Original languageEnglish
Pages (from-to)1086-1094
Number of pages9
JournalMultiple Sclerosis Journal
Issue number9
Publication statusPublished - Nov 2007


  • Clinically isolated syndrome
  • MBP antibodies
  • MOG antibodies
  • MRI
  • Multiple sclerosis
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS'. Together they form a unique fingerprint.

Cite this